Last reviewed · How we verify
Bedaquiline (B)
Bedaquiline (B) is a ATP synthase inhibitor Small molecule drug developed by Shenzhen Third People's Hospital. It is currently FDA-approved for Multidrug-resistant tuberculosis (MDR-TB), Extensively drug-resistant tuberculosis (XDR-TB). Also known as: BDQ.
Bedaquiline inhibits bacterial ATP synthase, disrupting energy production in Mycobacterium tuberculosis.
Bedaquiline is a small molecule inhibitor of ATP synthase, classified as an INHIBITOR. It is primarily used to treat Multi-drug Resistant Tuberculosis and Pulmonary Disease Due to Mycobacteria.
At a glance
| Generic name | Bedaquiline (B) |
|---|---|
| Also known as | BDQ |
| Sponsor | Shenzhen Third People's Hospital |
| Drug class | ATP synthase inhibitor |
| Target | Mycobacterial ATP synthase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Bedaquiline is a diarylquinoline that binds to the ATP synthase enzyme of tuberculosis bacteria, blocking ATP synthesis and causing rapid bactericidal activity. This mechanism is distinct from other TB drugs and is effective against both drug-susceptible and multidrug-resistant tuberculosis strains.
Approved indications
- Multidrug-resistant tuberculosis (MDR-TB)
- Extensively drug-resistant tuberculosis (XDR-TB)
Common side effects
- QT prolongation
- Hepatotoxicity
- Nausea
- Arthralgia
- Photosensitivity
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets (PHASE2)
- A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) (PHASE2, PHASE3)
- A PAN-USR TB Multi-Center Trial (PHASE3)
- Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection (PHASE1)
- B-PaLMZ for TB Meningitis (PHASE2)
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB (PHASE2)
- 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bedaquiline (B) CI brief — competitive landscape report
- Bedaquiline (B) updates RSS · CI watch RSS
- Shenzhen Third People's Hospital portfolio CI
Frequently asked questions about Bedaquiline (B)
What is Bedaquiline (B)?
How does Bedaquiline (B) work?
What is Bedaquiline (B) used for?
Who makes Bedaquiline (B)?
Is Bedaquiline (B) also known as anything else?
What drug class is Bedaquiline (B) in?
What development phase is Bedaquiline (B) in?
What are the side effects of Bedaquiline (B)?
What does Bedaquiline (B) target?
Related
- Drug class: All ATP synthase inhibitor drugs
- Target: All drugs targeting Mycobacterial ATP synthase
- Manufacturer: Shenzhen Third People's Hospital — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Multidrug-resistant tuberculosis (MDR-TB)
- Indication: Drugs for Extensively drug-resistant tuberculosis (XDR-TB)
- Also known as: BDQ
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing